Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Crinetics Pharmaceuticals (CRNX) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call at 4:30 p.m. ET, featuring management discussion of financial results and a business update.

Interested parties can join via phone using domestic (1-800-267-6316) or international (1-203-518-9783) dial-in numbers with Conference ID: CRNXQ4. Alternatively, participants can access a live webcast through the Events section of Crinetics' website. Participants are advised to connect 15 minutes before the call. The webcast will be archived on the company's Investor Relations section.

02/06/2025 - 04:35 PM

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Conference Call & Webcast

Thursday, February 27 @ 4:30 p.m. ET

Domestic: 1-800-267-6316
International: 1-203-518-9783
Conference ID: CRNXQ4

Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.

The webcast will be archived on the Investor Relations section of www.crinetics.com.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

FAQ

When will Crinetics Pharmaceuticals (CRNX) release Q4 and full year 2024 earnings?

Crinetics Pharmaceuticals will release its Q4 and full year 2024 financial results on Thursday, February 27, 2025, after the market closes.

What time is the CRNX Q4 2024 earnings conference call?

The earnings conference call is scheduled for 4:30 p.m. ET on Thursday, February 27, 2025.

How can investors access CRNX's Q4 2024 earnings call?

Investors can access the call via phone (domestic: 1-800-267-6316, international: 1-203-518-9783, Conference ID: CRNXQ4) or through a live webcast available on Crinetics' website.